» Articles » PMID: 35804953

Advances in Diagnosis and Therapy for Bladder Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jul 9
PMID 35804953
Authors
Affiliations
Soon will be listed here.
Abstract

Bladder cancer (BCa) is one of the most common and expensive urinary system malignancies for its high recurrence and progression rate. In recent years, immense amounts of studies have been carried out to bring a more comprehensive cognition and numerous promising clinic approaches for BCa therapy. The development of innovative enhanced cystoscopy techniques (optical techniques, imaging systems) and tumor biomarkers-based non-invasive urine screening (DNA methylation-based urine test) would dramatically improve the accuracy of tumor detection, reducing the risk of recurrence and progression of BCa. Moreover, intravesical instillation and systemic therapeutic strategies (cocktail therapy, immunotherapy, vaccine therapy, targeted therapy) also provide plentiful measures to break the predicament of BCa. Several exploratory clinical studies, including novel surgical approaches, pharmaceutical compositions, and bladder preservation techniques, emerged continually, which are supposed to be promising candidates for BCa clinical treatment. Here, recent advances and prospects of diagnosis, intravesical or systemic treatment, and novel drug delivery systems for BCa therapy are reviewed in this paper.

Citing Articles

Epithelioid Angiosarcoma of the Urinary Bladder After Brachytherapy for Prostatic Carcinoma: A Case Report and Literature Review.

Ramadhan A Cureus. 2025; 17(1):e77414.

PMID: 39958141 PMC: 11825224. DOI: 10.7759/cureus.77414.


Mechanistic insights of lenvatinib: enhancing cisplatin sensitivity, inducing apoptosis, and suppressing metastasis in bladder cancer cells through EGFR/ERK/P38/NF-κB signaling inactivation.

Chiang C, Yang J, Liu W, Chang F, Yang C, Hsu K Cancer Cell Int. 2025; 25(1):47.

PMID: 39955573 PMC: 11829490. DOI: 10.1186/s12935-024-03597-7.


Unveiling urinary extracellular vesicle mRNA signature for early diagnosis and prognosis of bladder cancer.

Sun N, Zhang Z, Yang X, Li J, Li Q, Kang J Theranostics. 2025; 15(4):1272-1284.

PMID: 39816677 PMC: 11729556. DOI: 10.7150/thno.107213.


CDC20 and CCNB1 Overexpression as Prognostic Markers in Bladder Cancer.

Sevim Nalkiran H, Biri I, Nalkiran I, Uzun H, Durur S, Bedir R Diagnostics (Basel). 2025; 15(1.

PMID: 39795587 PMC: 11719780. DOI: 10.3390/diagnostics15010059.


Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.

Jaszek N, Bogdanowicz A, Siwiec J, Starownik R, Kwasniewski W, Mlak R J Clin Med. 2024; 13(23).

PMID: 39685620 PMC: 11642161. DOI: 10.3390/jcm13237159.


References
1.
Shkolyar E, Jia X, Chang T, Trivedi D, Mach K, Meng M . Augmented Bladder Tumor Detection Using Deep Learning. Eur Urol. 2019; 76(6):714-718. PMC: 6889816. DOI: 10.1016/j.eururo.2019.08.032. View

2.
Erdbrugger U, Blijdorp C, Bijnsdorp I, Borras F, Burger D, Bussolati B . Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. J Extracell Vesicles. 2021; 10(7):e12093. PMC: 8138533. DOI: 10.1002/jev2.12093. View

3.
Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R . Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018; 36(34):3353-3360. DOI: 10.1200/JCO.18.01148. View

4.
Fernandez M, Brausi M, Clark P, Cookson M, Grossman H, Khochikar M . Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2018; 37(1):3-13. DOI: 10.1007/s00345-018-2436-y. View

5.
Miyake M, Nakai Y, Nishimura N, Ohnishi S, Oda Y, Fujii T . Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer. BJU Int. 2021; 128(2):244-253. DOI: 10.1111/bju.15368. View